Key result
Tocilizumab and corticosteroids achieve 3-year clinical remission in a patient with iMCD-TAFRO syndrome.
Why the study?
Idiopathic multicentric Castleman disease with TAFRO syndrome (iMCD-TAFRO) rarely involves the lungs.
Case Report (n=1)
Pulmonary manifestations in iMCD-TAFRO syndrome may reflect secondary fluid retention rather than primary lung disease, highlighting the need for comprehensive tissue evaluation.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for tocilizumab-corticosteroids in iMCD-TAFRO lung involvement; should not yet change practice.
Idiopathic multicentric Castleman disease with TAFRO syndrome (iMCD-TAFRO) rarely involves the lungs. We report the case of a 50-year-old man with persistent gastrointestinal symptoms who was found to have bilateral ground-glass opacities on chest CT. Despite prominent imaging abnormalities, a bronchoscopic lung biopsy revealed no inflammatory changes in the lungs. Bone marrow and lymph node biopsies confirmed the diagnosis of iMCD-TAFRO. Treatment with tocilizumab and corticosteroids resulted in clinical remission for 3 years. Pulmonary manifestations likely reflect secondary fluid retention rather than primary lung disease. This illustrates the importance of performing comprehensive tissue evaluations beyond a lung biopsy when systemic symptoms are accompanied by pulmonary findings.
No takes yet. Share an insight, caveat, or question.
Kami et al. (2026) conducted a case report in iMCD-TAFRO syndrome (n=1). Tocilizumab and corticosteroids was evaluated on Clinical remission. Treatment with tocilizumab and corticosteroids resulted in clinical remission for 3 years in a patient with iMCD-TAFRO syndrome presenting with bilateral ground-glass opacities.
Synapse has enriched 10 related papers. Consider them for comparative context: